Rchr
J-GLOBAL ID：200901017961111941
Update date: Mar. 04, 2023
Takamune Nobutoki
タカムネ ノブトキ | Takamune Nobutoki
Affiliation and department：
Research field (1)：
Pharmaceuticals - health and biochemistry
Papers (52)：
-
Higashi-Kuwata N, Tsuji K, Hayashi H, Bulut H, Kiso M, Imai M, Ogata-Aoki H, Ishii T, Kobayakawa T, Nakano K, et al. Identification of SARS-CoV-2 Mpro inhibitors containing P1' 4-fluorobenzothiazole moiety highly active against SARS-CoV-2. Nature communications. 2023. 14. 1. 1076-1076
-
Kohei Tsuji, Takahiro Ishii, Takuya Kobayakawa, Nobuyo Higashi-Kuwata, Chika Azuma, Miyuki Nakayama, Takato Onishi, Hiroki Nakano, Naoya Wada, Miki Hori, et al. Potent and biostable inhibitors of the main protease of SARS-CoV-2. iScience. 2022. 25. 11. 105365-105365
-
Naoki Kishimoto, Ryosuke Okano, Ayano Akita, Satoshi Miura, Ayaka Irie, Nobutoki Takamune, Shogo Misumi. Arginyl-tRNA-protein transferase 1 contributes to governing optimal stability of the human immunodeficiency virus type 1 core. Retrovirology. 2021. 18. 1. 30-30
-
Travis Chia, Tomofumi Nakamura, Masayuki Amano, Nobutoki Takamune, Masao Matsuoka, Hirotomo Nakata. A Small Molecule, ACAi-028, with Anti-HIV-1 Activity Targets a Novel Hydrophobic Pocket on HIV-1 Capsid. Antimicrobial agents and chemotherapy. 2021. 65. 10. e0103921
-
Naoki Kishimoto, Kengo Yamamoto, Towa Abe, Norito Yasuoka, Nobutoki Takamune, Shogo Misumi. Glucose-dependent aerobic glycolysis contributes to recruiting viral components into HIV-1 particles to maintain infectivity. Biochemical and biophysical research communications. 2021. 549. 187-193
ｍore...
MISC (3)：
Professional career (1)：
Return to Previous Page
